Articles

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, Amsterdam UMC, Amsterdam, the Netherlands
HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, University Medical Center Groningen, University of Groningen, the Netherlands
Department of Hematology, Isala Clinics, Zwolle, the Netherlands
Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands
Department of Hematology, UMC Utrecht Cancer Center, Utrecht, the Netherlands
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, University of Torino, Torino, Italy
Department of Hematology, Amsterdam UMC, Amsterdam, the Netherlands
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Vol. 104 No. 11 (2019): November, 2019 https://doi.org/10.3324/haematol.2018.205476